^
Association details:
| Biomarker: | HER-2 exon 20 insertion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Real-World Clinical Outcomes for Patients with EGFR and HER2 Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer
Published date:
07/25/2023
Excerpt:
Among HER2 ex20ins patients, 41/47 had stage IV disease….Of the seven patients who received poziotinib, two had a partial response and five had stable disease, and the one patient who received mobocertinib had stable disease, whereas one of the four patients who received afatinib had stable disease.
DOI:
https://doi.org/10.3390/curroncol30080515
